Search Results

ChemDiv Inc., dedicated to partnering in discovery and development of breakthrough therapies based on its unique chem-bio platforms, announces successful completion of Phase I clinical trials for AV5124, an innovative influenza virus replication inhibitor being developed by Viriom Inc. (Viriom).

Viriom Inc., dedicated to advancing a pipeline of highly effective and broadly affordable treatments targeting infectious and malignant diseases globally, announces the successful completion and positive results of Phase I clinical trial for AV5124, a novel inhibitor of influenza virus replication.

Viriom, Inc. announced the initiation of a Phase 2 clinical study to evaluate the efficacy of elsulfavirine in adults with moderate manifestations of COVID-19.

Viriom Inc announces the company’s activities to address the COVID-19 public health crisis, including supporting the experimental use of the HIV medicine, Elpida (elsulfavirine) and Viriom’s experimental flu medicines AV5080, AV5124 and AV5126 to determine their efficacy in the treatment of COVID-19.

Iain Dukes, CEO of Viriom Inc, presented Viriom’s strategy on high growth developing markets, which includes obtaining a market authorization in China, at the 11th ChinaBio Annual International Partnering Conference in Shanghai.

Viriom Inc., a San Diego CA-based biotech and Chromis, a joint venture of the ChemRar Group and the Russian Direct Investment Fund (RDIF) reported a summary of the multicenter, open-labeled, efficacy and safety study of Avifavir (favipiravir) in patients with COVID-19 at the Conference on Retroviruses and Opportunistic Infections CROI2021.

Viriom Inc (Viriom) announces launching Segment I and Segment II reproductive toxicity studies of Elpida® (elsulfavirine) HIV-1 therapy, supported by preclinical services of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

Viriom Inc., has won a grant award in the city of Shaoxing, Zhejiang province, to establish its affiliate in Mainland China.

Viriom Inc. is pleased to announce the appointment of Iain Dukes, M.A., D.Phil., as its new CEO. Dr. Dukes brings to Viriom over 20 years of extensive experience in drug discovery, pharmaceutical research and business development, as well as in leadership and consulting for numerous biotech and venture capital organizations.

Viriom Inc (San Diego, CA) signed a licensing agreement with P.T. Lloyd Pharma Indonesia as a part of its global strategy to help combat HIV drug resistance problem in developing markets by using innovative, safe and efficacious treatment and prevention options with Elpida® as well as other drugs from Viriom HIV and HBV portfolio.